Screener
Gilead Sciences GILD Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions, except per share amounts) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Cost of goods sold | 1,579 | 1,501 | 3,023 | 3,041 |
| Research and development expenses | 1,764 | 1,491 | 3,136 | 2,870 |
| Acquired in-process research and development expenses | 11,183 | 61 | 11,290 | 315 |
| In-process research and development impairments | 1,750 | 190 | 1,750 | 190 |
| Selling, general and administrative expenses | 1,921 | 1,365 | 3,372 | 2,623 |
| Total costs and expenses | 18,197 | 4,608 | 22,571 | 9,038 |
| Operating (loss) income | (10,394) | 2,474 | (7,808) | 4,711 |
| Interest expense | 247 | 254 | 487 | 513 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's impairment charges?
- Gilead Sciences (GILD) reported impairment charges of $1.75B in Q2 2026.
- How has Gilead Sciences's impairment charges changed year-over-year?
- Gilead Sciences's impairment charges increased by 821.1% year-over-year, from $190M to $1.75B.
- What does impairment charges mean?
- Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.
Ask your AI about Gilead Sciences's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude